drugset
drugset / Trial / NCT05879614

An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)

NCT05879614 ↗

Phase 2 Withdrawn Neuren Pharmaceuticals Limited
NaSingle-groupOpen-labelTreatment

Summary

A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Prader-Willi Syndrome.

Timeline

Start
2023-09-01
Primary completion
2025-06-30
Completion
2025-06-30

Outcome

Outcome not reported

Stopped (Business): “Revised development strategy”

Drugs

EvaluationDrugModalityDoseRoute
Subject NNZ-2591 Small molecule — Oral

Indications

Prader-Willi syndrome